Clinical trials and multi-center studies evaluating the TULSA-PRO procedure demonstrate high rates of targeted tissue removal, achieving over 90% efficacy in controlling localized disease progression alongside substantial reductions in prostate-specific antigen (PSA) levels. Furthermore, clinical follow-ups highlight exceptional functional preservation, with the vast majority of patients maintaining urinary continence and favorable recovery of sexual potency post-treatment.